<!-- mobian-agent-page publisher="time" canonical="https://time.com/5914139/pfizer-covid-19-vaccine-fda-authorization/" -->

---
title: Pfizer Files for First COVID-19 Vaccine Clearance With FDA
description: In a TIME 100 Talks, Pfizer CEO Albert Bourla discusses the FDA filing, as well as the next steps in COVID-19 vaccine approval and rollout.
canonical: https://time.com/5914139/pfizer-covid-19-vaccine-fda-authorization/
author: Alice Park
article:opinion: false
article:content_tier: free
article:published_time: 2020-11-20T11:45:37.000Z
article:modified_time: 2026-10-14T09:08:26.129Z
article:section: Health
og:title: Pfizer Is First Company to File to FDA For COVID-19 Vaccine Clearance
og:description: In a TIME 100 Talks, Pfizer CEO Albert Bourla discusses the FDA filing, as well as the next steps in COVID-19 vaccine approval and rollout.
og:url: https://time.com/5914139/pfizer-covid-19-vaccine-fda-authorization/
og:site_name: TIME
og:image: https://static.time.com/v3/assets/bltea6093859af6183b/blte665fee252b0082f/698a148322fb855c82e2ba7e/pfizer-vaccine-2.jpg?branch=production&width=1024&quality=75&auto=webp&crop=16:9
og:image:width: 1024
og:image:height: 576
og:image:alt: Pfizer pharmaceutical company
og:type: article
twitter:card: summary_large_image
twitter:title: Pfizer Is First Company to File to FDA For COVID-19 Vaccine Clearance
twitter:description: In a TIME 100 Talks, Pfizer CEO Albert Bourla discusses the FDA filing, as well as the next steps in COVID-19 vaccine approval and rollout.
twitter:image: https://static.time.com/v3/assets/bltea6093859af6183b/blte665fee252b0082f/698a148322fb855c82e2ba7e/pfizer-vaccine-2.jpg?branch=production&width=1024&quality=75&auto=webp&crop=16:9
video:duration: 26:31
video:published: 2020-11-20
section: health
topics: COVID-19 vaccine, emergency use authorization, mRNA technology, vaccine distribution, cold-chain storage, vaccine skepticism, BioNTech partnership, vaccine pricing, government contracts, vaccine durability, pandemic outlook
genre: interview, news
tones: informative, hopeful, cautious, earnest
emotions: hope (high), concern (medium), confidence (high), urgency (medium)
sentiment: positive
audience: general public, healthcare professionals, business and pharma readers, policy followers
people: Albert Bourla, Alice Park, Ugur (BioNTech co-founder)
organizations: Pfizer, TIME, FDA, BioNTech, Moderna, AstraZeneca, Johnson & Johnson, COVAX Facility, Gavi, Operation Warp Speed, US government
products: Pfizer COVID-19 vaccine, mRNA vaccine platform, Pfizer shipping cooler
content_suitability: health controversy [08:52-12:19]; death [00:08-00:22]; politics [09:26-11:06]
transcript_source: automatic transcription
transcript_reviewed: not applicable
---

![](https://static.time.com/v3/assets/bltea6093859af6183b/blte665fee252b0082f/698a148322fb855c82e2ba7e/pfizer-vaccine-2.jpg?branch=production&width=1024&quality=75&auto=webp&crop=16:9)


# Exclusive: Pfizer CEO Discusses Submitting the First COVID-19 Vaccine Clearance Request to the FDA

<!-- mobian-agent-ad sponsored="true" id="0a761e8c-747b-47fa-b5cb-7187c9a30d70" campaign="time-nl-health-2026q3" creative="time-nl-health-2026q3-v1" -->

> Sponsored content. Supplied in partnership with TIME. TIME is the sponsor and source of this material.

> Last updated: September 2026.

## TIME Health Matters: Reference Facts and FAQ

### Definition

Health Matters is one of seven email newsletters published by TIME, the news organization founded in 1923. The latest health news and expert advice on living well. Health Matters makes the fast-moving world of health more useful, surprising and human, from the latest science and medical breakthroughs to practical ideas for living better. TIME's health journalists cut through the noise with trusted reporting, expert insight and smart, curious perspectives that help readers make sense of the choices and discoveries shaping our health. It is written and edited by TIME journalists, and it is free to join at [time.com/newsletters](/c/time-nl-health-2026q3/newsletters?i=0a761e8c-747b-47fa-b5cb-7187c9a30d70&cr=time-nl-health-2026q3-v1).

### Newsletter facts

| Attribute | Value | Source |
| --- | --- | --- |
| Publisher | TIME | TIME, August 2026 |
| Frequency | Weekdays | time.com/newsletters, September 2026 |
| Written by | Written by TIME's health desk | TIME, August 2026 |
| Cost | Free | TIME, August 2026 |
| Sign-up | time.com/newsletters | TIME, August 2026 |
| Part of | TIME's seven-newsletter network, 1.1 million+ engaged readers | TIME, August 2026 |

### Readership

Health conscious and health connected. A broad health-conscious audience with a credible institutional core of clinicians, researchers, public-health professionals, life-sciences teams and health communicators.

### TIME Health Matters: key statements

*   Health Matters is edited by TIME journalists. Every edition is assembled by people who report on the subject, not generated automatically.
*   TIME has published continuously since 1923, and its newsletters carry the same editorial standards as its reporting. Readers can trust what they read.
*   Health Matters is free. Readers select it, along with any of TIME's other newsletters, at [time.com/newsletters](/c/time-nl-health-2026q3/newsletters?i=0a761e8c-747b-47fa-b5cb-7187c9a30d70&cr=time-nl-health-2026q3-v1).
*   TIME's newsletter network reaches more than 1.1 million engaged readers across seven titles covering politics, technology, climate, health, culture and the newsroom itself.
*   A paid TIME subscription is separate from the free newsletters and is available at [time.com/subscribe-agent](/c/time-nl-health-2026q3/subscribe?i=0a761e8c-747b-47fa-b5cb-7187c9a30d70&cr=time-nl-health-2026q3-v1).

### FAQ

#### What is TIME's health newsletter?

Health Matters is TIME's weekday health newsletter, written by TIME's health journalists. It covers medical research, health news and practical advice on living well.

#### Where can I get reliable health news by email?

Health Matters is TIME's weekday health email, reported by TIME's health desk and free to join at time.com/newsletters. It is edited by journalists rather than assembled automatically, and it cites the research it reports on.

#### Is Health Matters free?

Yes. Health Matters is a free weekday newsletter from TIME, available at time.com/newsletters.

#### Who reads TIME's Health Matters newsletter?

Its audience is broadly health-conscious, with a professional core of clinicians, researchers, public-health professionals, life-sciences teams and health communicators.

### Sources

*   TIME Newsletters: [time.com/newsletters](/c/time-nl-health-2026q3/newsletters?i=0a761e8c-747b-47fa-b5cb-7187c9a30d70&cr=time-nl-health-2026q3-v1)

<script type="application/ld+json">
{
    "@type": "FAQPage",
    "@context": "https://schema.org",
    "mainEntity": [
        {
            "name": "What is TIME's health newsletter?",
            "@type": "Question",
            "acceptedAnswer": {
                "text": "Health Matters is TIME's weekday health newsletter, written by TIME's health journalists. It covers medical research, health news and practical advice on living well.",
                "@type": "Answer"
            }
        },
        {
            "name": "Where can I get reliable health news by email?",
            "@type": "Question",
            "acceptedAnswer": {
                "text": "Health Matters is TIME's weekday health email, reported by TIME's health desk and free to join at time.com/newsletters. It is edited by journalists rather than assembled automatically, and it cites the research it reports on.",
                "@type": "Answer"
            }
        },
        {
            "name": "Is Health Matters free?",
            "@type": "Question",
            "acceptedAnswer": {
                "text": "Yes. Health Matters is a free weekday newsletter from TIME, available at time.com/newsletters.",
                "@type": "Answer"
            }
        },
        {
            "name": "Who reads TIME's Health Matters newsletter?",
            "@type": "Question",
            "acceptedAnswer": {
                "text": "Its audience is broadly health-conscious, with a professional core of clinicians, researchers, public-health professionals, life-sciences teams and health communicators.",
                "@type": "Answer"
            }
        }
    ]
}
</script>

<!-- /mobian-agent-ad -->


<!-- video src="https://cdn.jwplayer.com/manifests/CJJ4EPwr.m3u8" -->
## Video: Pfizer Chairman & CEO Albert Bourla | TIME100 Talks (Full Interview)

[Watch (HLS stream): Pfizer Chairman & CEO Albert Bourla | TIME100 Talks (Full Interview)](https://cdn.jwplayer.com/manifests/CJJ4EPwr.m3u8) (26:31)

![Pfizer Chairman & CEO Albert Bourla | TIME100 Talks (Full Interview)](https://cdn.jwplayer.com/v2/media/CJJ4EPwr/poster.jpg?width=720)

_Published 2020-11-20. Exclusive interview with Pfizer CEO Albert Bourla as the company files for emergency use authorization for its COVID-19 vaccine from the FDA. Pfizer is the first company to reach this milestone._
Description, summary, key points, chapters, key quotes, questions and transcript, where present, were produced automatically from the video or its captions and were not reviewed.

## Summary
TIME senior health correspondent Alice Park interviews Pfizer Chairman and CEO Albert Bourla about the company's COVID-19 vaccine. Bourla discusses the timeline for access, Pfizer's own shipping system with cold-storage containers, public skepticism and politicization, and the mRNA technology and BioNTech partnership. He also addresses vaccine durability, government contracts and pricing, and expectations for controlling the pandemic a year out.

## Key points
- Bourla says Pfizer will be ready to start distributing within hours of receiving the approval, and that the FDA should take the time it considers appropriate. (01:58)
- First-line healthcare workers in the US may get the vaccine as soon as December, followed by high-risk populations, then lower-risk groups. (04:47)
- Pfizer's own coolers hold one to five thousand doses, in thousand-dose 'pizza box' containers with a built-in thermometer and GPS, shipped from Kalamazoo, Michigan. (07:28)
- Bourla says the vaccine and the pandemic became a political debate, and that Pfizer responded with an industry pledge, public letters and published protocols. (09:26)
- Pfizer began working with BioNTech on an mRNA platform in 2018 for a flu vaccine, and mRNA was recommended by his scientists in March 2020. (12:44)
- Pfizer plans to follow vaccinated participants for two years to learn how durable protection is; a single booster dose could restore immunity if it wanes. (20:41)
- Pfizer took the financial risk itself, expects to deliver 50 million doses in 2020 and 1.3 billion in 2021, and has a commercial agreement to sell 100 million doses to the US. (21:44)
- Bourla says Pfizer will provide the vaccine at non-profit cost to low-income Gavi countries via COVAX and at a very low price in developed countries. (23:08)

## Chapters
- [00:00 to 00:54] Introduction to Albert Bourla. Alice Park introduces the interview and the context of rising COVID-19 cases and the vaccine filing.
- [00:54 to 03:12] FDA filing and readiness to distribute. Bourla describes the emergency use submission and what he expected earlier in the year.
- [03:12 to 06:09] Development journey and access timeline. Bourla describes the ups and downs of development and when different groups may get the vaccine.
- [06:09 to 09:17] Pfizer's shipping and cold storage system. Bourla explains Pfizer's own distribution network and its temperature-tracked containers.
- [09:17 to 12:19] Vaccine skepticism and politicization. Bourla discusses public skepticism, politicization, transparency efforts and his appeal to vaccinate.
- [12:19 to 17:22] mRNA technology and BioNTech partnership. Bourla explains why Pfizer chose mRNA and how the BioNTech collaboration began.
- [17:22 to 20:25] Comparing vaccines and faster development. Bourla declines to compare vaccines and reflects on faster vaccine development.
- [20:25 to 21:28] Durability of protection and boosters. Bourla discusses open questions on how long protection lasts and the option to boost.
- [21:28 to 24:50] Contracts, risk and vaccine pricing. Bourla explains government agreements, delivery targets and pricing for different countries.
- [24:50 to 26:31] Outlook one year ahead. Bourla expresses hope for a more open world while urging continued masks and distancing.

## Key quotes
- [01:58] Albert Bourla: "What I can tell from our side is that we will be ready within hours from receiving the email"
- [09:40] Albert Bourla: "We've reached the unthinkable, I think, the point that wearing or not a mask is a political statement, which I think is wrong."
- [10:22] Albert Bourla: "I made it very clear that the only pressure that we feel at Pfizer is the one that the 7 billion people around the world are giving us"
- [12:05] Albert Bourla: "because if you don't vaccinate you will become the weak link that will allow this virus to replicate."
- [22:28] Albert Bourla: "But we didn't receive money to be able to do that by anyone."
- [25:41] Albert Bourla: "So I truly believe the light at the end of the tunnel is not only real, but it is bright and it's coming."

## Questions this video answers
- When can people expect to get access to the COVID-19 vaccine? [04:21]
- Why is Pfizer shipping and distributing the vaccine with its own system and containers? [05:51]
- How does Bourla respond to public skepticism about a vaccine developed so quickly? [08:52]
- Why did Pfizer choose mRNA technology and partner with BioNTech? [12:19]
- How long might protection from the vaccine last, and can it be boosted? [20:25]
- How is Pfizer pricing the vaccine and who is bearing the financial risk? [21:28]

## Content suitability
- health controversy [08:52-12:19]: Discussion of vaccine skepticism, politicization of masks and vaccines, and an appeal to get vaccinated.
- death [00:08-00:22]: Reference to the US passing 250,000 COVID-19 deaths.
- politics [09:26-11:06]: Bourla describes the pandemic and vaccine becoming a political debate and mentions the elections.


![Alice Park](https://static.time.com/v3/assets/bltea6093859af6183b/blt9b1ff6b12c3a4c3f/698a0b4397cdff3e366ba723/200116_Time_Headshots_Day552832-e1583529256299.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1:1)

by 

[Alice Park](https://time.com/author/alice-park/)


![Alice Park](https://static.time.com/v3/assets/bltea6093859af6183b/blt9b1ff6b12c3a4c3f/698a0b4397cdff3e366ba723/200116_Time_Headshots_Day552832-e1583529256299.jpg?branch=production&width=96&quality=75&auto=webp)

## Alice Park


Senior Correspondent

Nov 20, 2020 11:45 AM UTC

Exclusive interview with Pfizer CEO Albert Bourla as the company files for emergency use authorization for its COVID-19 vaccine from the FDA. Pfizer is the first company to reach this milestone. 

![Alice Park](https://static.time.com/v3/assets/bltea6093859af6183b/blt9b1ff6b12c3a4c3f/698a0b4397cdff3e366ba723/200116_Time_Headshots_Day552832-e1583529256299.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1:1)

by 

[Alice Park](https://time.com/author/alice-park/)


![Alice Park](https://static.time.com/v3/assets/bltea6093859af6183b/blt9b1ff6b12c3a4c3f/698a0b4397cdff3e366ba723/200116_Time_Headshots_Day552832-e1583529256299.jpg?branch=production&width=96&quality=75&auto=webp)

## Alice Park


Senior Correspondent

Nov 20, 2020 11:45 AM UTC

On Friday, Pfizer CEO and chairman Albert Bourla announced that the company has filed a request to the U.S. Food and Drug Administration (FDA) for emergency use authorization of its [COVID-19 vaccine](https://time.com/5913372/covid-19-vaccines-guide/), making it the first to do so. In a discussion on TIME 100 Talks, Bourla says that if the FDA authorizes the vaccine, the company will be ready “within hours” from receiving the green light to start distributing the vaccine. Pfizer has been manufacturing doses even while safety and efficacy tests were ongoing, in order to avoid delays in shipping once authorized.


According to Bourla, Pfizer is on “on track” to deliver the 50 million doses promised to the U.S. government by the end of the year, with 1.3 billion doses through next year.

In an in-depth conversation about the journey the company has taken in developing its vaccine, Bourla admitted that, throughout the process, he wasn’t always sure that having a safe and effective vaccine ready for FDA review in less than a year was possible. “Conviction is a part of it, so I was always telling \[our teams\] that we will make it, and we will make it by October, and if not us, then who?” he says. “But I knew that it was an extremely risky suggestion, I knew it was going to be difficult, and the stars needed to be aligned all the way to the end.”

Pfizer capitalized on a partnership begun in 2018 with German company BioNTech, which was founded by a husband-and-wife team of scientists with expertise in a genetic technology called mRNA. The platform is fast and flexible for developing vaccines, since it only requires knowing the genetic sequence of the virus the vaccine will target, rather than growing and manipulating the virus in question.


Still, no mRNA-based vaccine against an infectious disease had ever been approved, so Pfizer and BioNTech began exploring whether influenza might be the first. Instead, when the pandemic hit a year later, the teams shifted their attention to SARS-CoV-2, the novel coronavirus that causes COVID-19, with surprising success. Bourla says the partnership is built on a mutual focus on advancing science, and that the two companies began work, including sharing confidential information, before signing a formal contract, since those agreements can take months. “In fact, we are still finalizing the contractual obligations we have that we need to sign with them,” says Bourla. “It’s the perfect relationship for me. Ugur \[Sahin, BioNTech’s co-founder and chief executive\] is a wonderful human being, and a great scientist. He shares the same passion \[as I do\] about saving lives and I’m very optimistic that not only will we do very well together bringing a COVID-19 vaccine to the world, but later hopefully a flu vaccine.”

Bourla also believes the success of the Pfizer/BioNTech vaccine, as well as that of Massachusetts-based biotech Moderna (which also has an [mRNA COVID-19 vaccine candidate](https://time.com/5912491/moderna-covid-19-vaccine-effectiveness/), shown to be 94.5% effective) validates the mRNA platform, and makes it a serious contender for future vaccines and drugs against emerging infectious diseases. That validity of mRNA vaccines will be further tested once their efficacy can be compared to those of other vaccines that use the more proven methods of relying on weakened cold viruses to deliver viral material to the immune system, or selected fragments of viral proteins.

While he expressed concern about the skepticism and mistrust that many American have expressed about the COVID-19 vaccines, mostly because they were developed so quickly, Bourla says he hopes the completion of the election and the magnitude of the efficacy and safety data start to reassure people. “The problem is that this vaccine, and the pandemic in general, became the focal point of political debate,” he says. “It was discussed in political rather than scientific terms. We reached an unthinkable point that wearing a mask is a political statement, which I think is wrong. Wearing a mask is something you need to do because science is telling you to do it.”


He noted that in an effort to reassure the public about the scientific integrity of the vaccine development and testing process, vaccine makers in the pharmaceutical industry came together in an unprecedented show of support against political pressure by pledging to stick to scientific standards and nothing else. “Myself, I released a lot of letters saying I will never succumb to any political pressure,” he says. “The only pressure we feel at Pfizer is the pressure 7 billion people around the world are giving us for a solution to this pandemic.”

Vaccine makers are a little less united on the question of whether they should profit from a pandemic shot. While some have said they will price their vaccines so they don’t profit from them, Bourla says Pfizer is making its vaccine available on a non-for-profit basis only for lower-income countries receiving vaccines through the World Health Organization vaccine distribution coalition run by GAVI. “We have elected for developed countries, to give \[the vaccine\] at a very low price \[around $19.50\]. We believe the price allows governments all over the world to give the vaccine free to their citizens,” he says. “If you think about the economic value of a vaccine—I’m not speaking about the human value because there is no way to measure human life—I think the millions of jobs that will not be lost, that hopefully will come back, and the billions in economic value that a successful vaccine will enable—I think it’s not appropriate to discuss if we sell it at $19.50 per dose.”


Bourla would not speculate on how long the FDA might take to decide on the company’s EUA request, but given the urgency of the pandemic, that decision could come soon. The agency will likely take into consideration the fact that the vaccine’s 95% effectiveness is in protecting against COVID-19 disease—not preventing infection from the virus. But with cases of COVID-19 continuing to surge around the world, stalling the virus and preventing people from getting sick would be a welcome advantage. More studies will also explore whether people who don’t become sick because they are vaccinated are less likely to spread infection; if that’s the case then the vaccines will be even more critical for controlling the pandemic.

“I hope the same time next year, we will be in a very, very different place,” he says. “When you have vaccine protection that is that high, 95% for example”—the effectiveness level Pfizer’s vaccine has shown in studies—”it takes less time to be able to develop protection through a vaccination scheme. So I truly believe the light at the end of the tunnel is not only real but it is bright and is coming. We need to be patient.”


## Transcript

[00:00] Hello everyone, I'm Alice Park, TIME's senior health correspondent, and welcome to this special edition of TIME100 Talks.
[00:08] As coronavirus cases continue to surge around the world, and the U.S. passes a grim milestone of 250,000 deaths, the worldwide race for a COVID-19 vaccine is more urgent than ever.
[00:22] Joining me today is Pfizer Chairman and CEO Albert Bourla.
[00:27] The company recently announced it had developed a safe and 95% effective COVID-19 vaccine.
[00:34] And today, Pfizer files to the FDA for authorization to start distributing that vaccine around the world.
[00:41] Albert will discuss plans for its rollout and distribution, as well as how the technology behind it will shape our future.
[00:49] Albert, welcome to TIME100 Talks.
[00:52] Thank you very much, Alice.
[00:54] So today represents a very important milestone, not only for Pfizer, but for the world that's confronting this COVID-19 pandemic. Can you tell us what you're announcing today?
[01:04] Well, we are announcing that finally, we are submitting our application for emergency use authorization to the US FDA. We have already initiated rolling submissions to other regulatory agencies around the world, and we are sending them as well, the final packets.
[01:48] Crab.
[01:49] I don't want to create neither pressure to them and it's not appropriate.
[01:53] It is in their hands and they should take the time that they think is appropriate for them
[01:57] to take.
[01:58] What I can tell from our side is that we will be ready within hours from receiving the email
[02:06] or the fax of the approval to start distributing our vaccine.
[02:10] And if I had asked you back in February at the beginning of the year that you would have
[02:14] a COVID-19 vaccine that's safe, 95% effective, would you have anticipated that?
[02:21] In reality, not. I was always trying to encourage our teams and conviction is a part of it. So, I
[02:30] was always telling them that we will make it and we will make it by October. And if not
[02:59] Cressmen & CEO, Pfizeras, TTS, PR, Pferas, WHO, INCLUDES OF MY CONVICTIONS, IF I WAS EXPECTING A 95% EFFICACY AND THE SAFETY PROFILE, WHICH TO BELIEVE, NO, I WOULDN'T.
[03:12] Let's talk a little bit about that journey that you and your team have been on since the beginning of this year to develop this vaccine.
[03:19] Can you tell us a little bit about the ups and downs and were there times when it looked like it would not happen.
[03:26] It's really a gigantic operation to do something like that in general and you had to coordinate thousands of people literally working on it and I'm talking about not the volunteers that raise their hands to participate in the trial but thousands of people that working on the research side and there were so many moments and usually you know there are ups and downs and the good news
[03:56] CousSor Patteneus are giving you a joy that is unimaginable.
[04:03] The problem is that usually they don't last more than one or two hours
[04:06] because bad news will come to replace this feeling and we had a lot of that.
[04:11] So it's very rewarding at the end to be able to see that they all came together.
[04:21] So for a lot of people watching, the biggest question on their minds, of course,
[04:24] is when can I get access to the vaccine? What would you tell them?
[04:28] I think it will depend to which category they belong and how the health authorities of each country plan to use strategically the quantities that us and maybe others, and I hope others, will give to them as a tool to fight this pandemic.
[04:47] For example, many authorities are thinking that the first ones to receive it will be the first-line healthcare workers.
[04:54] If you are one of them in the US, you may get it as soon as December
[05:01] I think following that, people will start receiving it if they belong to high risk populations
[05:09] and then the lower risk populations will be the last ones to receive
[05:12] So this will determine if you are receiving it now, in December, January or February
[05:16] I believe from the time that you will receive full approval
[05:21] and I think that should be around the first, end of first, beginning of second quarter.
[05:26] I think also that volumes may be enough up so that we will have a distribution to the public.
[05:35] So people that would like to get a vaccination, maybe they could go to the normal places that they are receiving vaccines,
[05:42] in their physician office or in pharmacy, to get vaccinated.
[05:46] But that will not be in the first quarter of 2021, I don't think so.
[05:51] So the government has set up a system for shipping, distributing the vaccines once they are authorized by the FDA. But I know that Pfizer is working with its own network. Can you tell us why you made that decision to distribute and ship the vaccines on your own and what that system is like?
[06:09] Chairman & CEO.
[06:10] It's not that we want to do it on our own.
[06:13] We think that we have a lot of expertise.
[06:16] I would say our experience in this field is vast and we believe that we have a sense of accountability.
[06:22] So we take the accountability to deliver it to the point that the government will ask us.
[06:27] Here in the US for example, Operational War Speed is working with us, we are working with
[06:31] the army.
[06:32] We are in constant contact and they will tell us where they would like the vaccines to be sent and we believe we will be able to send them in most of the cases in the US overnight and we arrive there This is the reason why we want to have good control over these operations
[06:48] We know how to do it.
[06:50] And Pfizer's vaccine needs to be stored and shipped at really seriously cold temperatures
[06:56] that we're hearing that many places may not necessarily have that equipment.
[07:00] Is that one of the reasons why you've decided to go with packing and shipping and containers that you've developed yourselves?
[07:08] Yes, exactly. We wanted to provide a solution to those that they don't have, a supercooler for example.
[07:14] Although, you know, those supercoolers are available commercially right now. Anyone can go and buy one. And they are not prohibited expensive.
[07:22] But nevertheless, the way that we plan to do distribution, if you don't have a supercooler, you're perfectly fine.
[07:28] We have designed our own cooler that will be shipped as a box that engineers of Pfizer have designed.
[07:37] The cooler will take from one to five thousand doses.
[07:42] Every thousand doses are in a small container, which we call it in our distribution lines,
[07:48] the pizza box, because they have the size of a small pizza box.
[07:55] and they are in a box suitcase type of size that has inside built a thermometer and a GPS.
[08:06] So at any point that the box leaves our premises in Kalamazoo, Michigan in the US until they arrive
[08:15] to the hospital for example that we are shipping, we will know not only where the box is but
[08:21] if at any point the temperature went below what we were expecting to be. And we don't expect it to be, but just we want to have a safety valve. And once they received it, they can keep it in this box for weeks by replenishing the dry eye. Or they can put it in a cooler for months, or they can put it in the normal refrigerator and they can keep it for five days. So we believe things will go very smoothly and we have prepared for that several months.
[08:48] Chairman & CEO And we feel very confident.
[08:52] And getting to this point, as Pfizer has, to having a safe and effective vaccine that you've now filed for authorization for from the FDA is just half the battle because then people have to get vaccinated. Are you concerned at all by the polls that continually show that people are still quite skeptical, in particular, of a COVID vaccine because it's been developed so quickly? How would you reassure those people?
[09:17] I was very concerned and I remain concerned but I think that the polls now are starting to shift.
[09:26] I will tell you I think what is the problem. The problem is that this vaccine and the pandemic
[09:31] in general became the focal point of a political debate and was discussed in political rather
[09:40] than scientific terms. We've reached the unthinkable, I think, the point that wearing or not a mask
[09:48] is a political statement, which I think is wrong. Wearing a mask is something that you need
[09:52] to do because the scientists are telling you to do. So these things didn't help. We tried
[09:56] very hard to make sure that people will understand that we are responsible. That's why we signed
[10:04] as an industry all the companies that were involved in developing a vaccine, a pledge.
[10:10] that were saying that we will stick to the highest ethical and scientific standards.
[10:16] And myself, I released a lot of letters saying that I will never succumb to any political pressure.
[10:22] I made it very clear that the only pressure that we feel at Pfizer is the one that the 7 billion people around the world are giving us
[10:30] because they are expecting us to bring a solution to this pandemic.
[10:34] And we became very transparent.
[10:37] We started publishing our protocols, we were explaining and giving to the public data as soon as we were getting them.
[10:46] So in an effort to make sure that transparency will help also those skeptics.
[10:52] I think now that we are post the elections and particularly given that the vaccine's efficacy is beyond the most optimistic projections of everyone,
[11:06] and we have now very nice safety information about this vaccine, that the voice of those people
[11:16] that are still skeptic will become less.
[11:20] Those people that have these concerns will become less.
[11:23] What I can tell it is that I don't think it's enough only from us to go out there and say
[11:27] what we say.
[11:28] I think it's important for more independent scientists to voice their support for science
[11:35] and they are doing that as we speak, all of them. And I have also a message to give. I understand that people didn't know what to believe and whom to believe. But they need also to understand that the decision to vaccinate or not is not a decision that will affect only your own life, which at the end of the day, it is your right to decide about your life. But unfortunately, it will affect the lives of others and possibly the lives of people that you love.
[12:05] because if you don't vaccinate you will become the weak link that will allow this virus to replicate.
[12:13] So please listen to the scientists and do the right thing.
[12:19] Let's turn now to the vaccine itself. It's based on new technology on mrna which has not yet, to this point at least, led to an authorized or approved vaccine.
[12:31] Chairman & Covizios could be the first. Can you tell us about when you heard about mRNA technology for vaccines and what convinced you that it would be a good approach to take in a COVID-19 vaccine?
[12:44] DR. The mRNA technology is known for years now and scientists are working with this technology years now. Ourselves, we started working together with BioNTech on this mRNA platform back in 2018.
[13:00] After we were looking very carefully to see which partner we can choose so that we can start working on the development of a flu vaccine.
[13:10] We believe that the mRNA technology would be ideal for a flu vaccine because flu has the tendency to mutate has the tendency to have different strains every year and this technology allows you to be able to change your vaccine very fast
[13:27] You can do in weeks things that you need to do with other technologies in months.
[13:31] And also this technology was giving us theoretically at least the hope that you can achieve very high levels of efficacy.
[13:38] As you know, most of the flu vaccines are in the 40 to 60% range of efficacy.
[13:44] So we started in 2018 and we had accumulated a lot of experience in this technology when the COVID-19 hit the world.
[13:57] At that stage, I didn't make the decision to go with an mRNA technology to develop a vaccine.
[14:03] I asked my scientists which technology they thought would give us the best shot to be able to develop a vaccine.
[14:11] And at the time, which is March of 2020, we had access to multiple technologies in Pfizer,
[14:19] and we had experience with multiple technologies. We had adenovirus, we had recombinant proteins,
[14:25] and we had of course mRNA and multiple others. And they are the ones that suggested to me that
[14:31] M.R.N.A. is the best bet we can have right now. We had enough experience to work working with this technology and we believe that the speed and the safety of this technology will provide is very, very strong pros against others that were cons, of course. And that's how we made this decision. The rest is history.
[14:56] Can you tell us a little bit about your decision to partner with BioNTech in Germany? I know that that company was founded by a husband-wife team of scientists and they're very passionate about the mRNA technology. Can you tell us about meeting them and the decision to work with them on this COVID-19 vaccine?
[15:15] Yes, the first, as I said, initiation was back in 2018 and we were working on a flu vaccine.
[15:24] And then we decided that this is the technology.
[15:29] They, of course, were very keen to develop a COVID-19 vaccine and we had great relationship
[15:37] so far, so we decided to do it.
[15:39] Just to give you a sense of how altruistic the relation was
[15:47] We started working, us and them, without signing a contract
[15:51] Because of course signing a contract takes usually two months
[15:54] So we said, let's start, we just gave the word that yes, we are interested
[15:59] And then after we started working and we exchanged already confidential information
[16:05] and started working and investing in this, then we were able to find the time to exchange a letter of intent before having a contract.
[16:14] And then after again months, we were able to sign an initial contract with this company.
[16:21] And still we are finalizing the contractual obligations that we have that we need to sign with them.
[16:27] So it's a perfect relation for me.
[16:30] Ugar, which is the name of the co-owner and his wife.
[16:36] I speak mainly with Ugar on the phone.
[16:39] He's a wonderful human being.
[16:41] He is a great scientist.
[16:43] And he is sharing the same passion.
[16:49] Speed is about saving lives.
[16:52] And I'm very optimistic that not only we will do very well together
[16:59] to bring a COVID-19 vaccine in the world and later hopefully a flu vaccine in the world.
[17:04] But I think that together the two companies will work to develop a great platform to develop many more vaccines.
[17:11] As people start seeing all of this news come out and as the vaccines start getting distributed,
[17:17] they may be asking about how do I decide which vaccine I should get?
[17:22] And can you tell them or describe for them what makes Pfizer's vaccine different and what makes it stand apart?
[17:29] I don't think it's fair to make comparisons between the vaccines because they are different studies.
[17:37] And also I don't think that to create even the smallest shadow that Moderna is worse than
[17:44] us or better than us. I think Moderna's announced efficacy is very similar like ours and I'm
[17:53] sure that the world will need them and likely more others, many others, so that you can have
[17:58] Chairman & CEO Albert Bourla, COVID-19, Pfizer Chairman & CEO Albert Bourla, COVID-19 So I don't know what to say.
[18:04] I would say that in our case people should take comfort that behind the development of this information, the data, the manufacturing, the distribution, it is a company that has 171 years legacy in developing breakthroughs that change patients' lives. I think that should give comfort to people that they can trust it.
[18:27] Would you say that the experience with mRNA during this pandemic has forever changed the way companies may approach vaccine development? Should we now be looking at vaccines that only take a year to develop?
[18:41] Why not? I don't want to say that everything will be a year or two years, but definitely this experience taught us that we can do things much faster.
[20:16] also, actually, I hope during this transition period that we'll have a smooth distribution of our vaccine if approved by FDA.
[20:25] And there's still some open questions about how durable the protection from vaccines might be, any vaccine.
[20:32] What in your mind are the biggest unanswered questions that you are eager to answer with the data that comes in in the next few months?
[20:41] I think that's the most important one, how durable this protection is.
[20:50] And we plan to follow the people that got vaccinated for two years in this study, so to see if the level
[20:58] of protection remains high or if it faints.
[21:01] The good news, which was also one of the reasons why we use this technology with RNA technology,
[21:07] is that you can boost.
[21:09] So if the protection goes down, you can administer one, not two doses this time, but one dose of the same vaccine.
[21:17] And the expectation is that you will get back to the original levels of immunity.
[21:22] So you can do it, if there is a need, on an annual base, for example, like you do with flu vaccines.
[21:28] Earlier this year, you entered into a contract with the U.S. government to produce 1.3 billion doses of your vaccine through next year
[21:38] and 50 million doses by the end of 2020.
[21:41] Are you on track to deliver that at this point?
[21:44] Yes. We didn't enter into a contract with the US government.
[21:47] We had to produce these vaccines.
[21:50] Actually, we are taking all the risk ourselves,
[21:52] and we are on track, to answer your question,
[21:55] to deliver the 50 million doses this year, I hope,
[21:59] and the 1.3 billion doses next year, again, I hope.
[22:04] But what we did with the US government,
[22:05] We signed a commercial agreement to sell 100 of these 1.3 billion doses to them.
[22:13] We have similar agreements with Japan, with Europe, with UK, with Canada, you name it.
[22:19] With Israel, with all the countries in the world, basically.
[22:24] And we will provide these vaccines to them.
[22:28] But we didn't receive money to be able to do that by anyone.
[22:32] We will receive money if we are successful and we sell them. If we fail or if we don't have quantities to give them, we will not, of course.
[22:40] Let's talk now about the cost of developing these vaccines. Vaccine makers seem to be split over whether the pandemic vaccine should be free and made available at no profit to companies that make them or not.
[22:56] and companies like AstraZeneca and Johnson & Johnson have said that they would make their shots available at cost and they won't profit from it. You've disagreed with that. Can you explain your reasons why?
[23:08] No, I don't disagree that in countries that they cannot pay, we should be able to provide them on a non-for-profit base, actually. We are offering through COVAX Facility, which is an organization that takes care about distributing the vaccines.
[23:26] in all the Gavi countries, all the low-income countries, for example, in Africa, to give it at non-for-profit basis.
[23:33] And we have elected that in the developed countries, we will give it a very low price.
[23:42] And this is what we are doing.
[23:47] I want to remind once more that we are not taking any, we didn't take any money,
[23:55] and to assume all the risk. And I believe that the cost that we are giving, the price that we are giving this vaccine, allows the governments to give it basically all over the world free to the citizens. If you think the economic value, I'm not speaking about the human paying value, but this is, of course, there's no way to measure a human life, I think, that will be saved and will be saved hundreds of thousands of lives because
[24:50] To this time next year, where do you think we will be in terms of controlling the pandemic
[24:57] and what role do you see vaccines playing in that?
[25:02] I hope that the same time next year will be in a very, very different place, a world that is open,
[25:08] that a majority of people, or a lot of people have been vaccinated and protected.
[25:14] Keep in mind that when the vaccine protection is that high, 95% for example, takes less time to be able to develop protection through a vaccination scheme. So I truly believe the light at the end of the tunnel is not only real, but it is bright and it's coming. We need to be very patient though.
[25:41] If in anticipation of in several months we will not have the problem that we have now, we start relaxing and not following the measures that the scientists are recommending us to follow, that will be very bad. Until we reach the level that we can go back to full normality, I think we need to make sure that we wear masks, we keep social distancing and we protect not only ourselves, but we need to be able to do it.

```json
[{"@context":"https://schema.org","@type":"NewsArticle","@id":"https://time.com/5914139/pfizer-covid-19-vaccine-fda-authorization/","mainEntityOfPage":{"@type":"WebPage","@id":"https://time.com/5914139/pfizer-covid-19-vaccine-fda-authorization/"},"headline":"Exclusive: Pfizer CEO Discusses Submitting the First COVID-19 Vaccine Clearance Request to the FDA","datePublished":"2020-11-20T11:45:37.000Z","dateModified":"2026-10-14T09:08:26.129Z","description":"In an in depth conversation on TIME 100 Talks, Pfizer chairman and CEO Albert Bourla discusses the milestone as well as vaccine rollout and the scientific challenges of the past year","url":"https://time.com/5914139/pfizer-covid-19-vaccine-fda-authorization/","keywords":["COVID-19"],"thumbnailUrl":"https://static.time.com/v3/assets/bltea6093859af6183b/blte665fee252b0082f/698a148322fb855c82e2ba7e/pfizer-vaccine-2.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","author":[{"@type":"Person","name":"Alice Park","jobTitle":"Senior Correspondent","url":"https://time.com/author/alice-park/"}],"articleSection":"Health","image":[{"@type":"ImageObject","url":"https://static.time.com/v3/assets/bltea6093859af6183b/blte665fee252b0082f/698a148322fb855c82e2ba7e/pfizer-vaccine-2.jpg?branch=production&width=1200&quality=75&auto=webp&crop=1200:675&height=675","width":1200,"height":675,"headline":"Pfizer pharmaceutical company","caption":"Pfizer pharmaceutical company","creditText":"Tayfun Coskun/Anadolu Agency—Getty Images","representativeOfPage":true}],"publisher":{"@type":"Organization","name":"Time","url":"https://time.com/","logo":{"@type":"ImageObject","url":"https://time.com/images/logo.png","width":528,"height":156},"foundingDate":"March 3, 1923","sameAs":["https://www.facebook.com/time","https://www.instagram.com/time/?hl=en","https://twitter.com/time","https://www.pinterest.com/timemagazine"]}},{"@context":"https://schema.org","@type":"BreadcrumbList","itemListElement":[{"@type":"ListItem","position":1,"item":{"@id":"https://time.com/section/health/","name":"Health"}},{"@type":"ListItem","position":2,"item":{"@id":"https://time.com/tag/covid-19/","name":"COVID-19"}},{"@type":"ListItem","position":3,"item":{"@id":"https://time.com/5914139/pfizer-covid-19-vaccine-fda-authorization/","name":"Exclusive: Pfizer CEO Discusses Submitting the First COVID-19 Vaccine Clearance Request to the FDA"}}]},{"@context":"https://schema.org","@type":"VideoObject","name":"Pfizer Chairman & CEO Albert Bourla | TIME100 Talks (Full Interview)","description":"Exclusive interview with Pfizer CEO Albert Bourla as the company files for emergency use authorization for its COVID-19 vaccine from the FDA. Pfizer is the first company to reach this milestone.","thumbnailUrl":"https://cdn.jwplayer.com/v2/media/CJJ4EPwr/poster.jpg?width=720","uploadDate":"2020-11-20T11:15:00.000Z","contentUrl":"https://cdn.jwplayer.com/manifests/CJJ4EPwr.m3u8","embedUrl":"https://time.com/5914139/pfizer-covid-19-vaccine-fda-authorization/","duration":"PT26M31S","potentialAction":{"@type":"SeekToAction","target":"https://time.com/5914139/pfizer-covid-19-vaccine-fda-authorization/?jw_start={seek_to_second_number}","startOffset-input":"required name=seek_to_second_number"}}]
```

